RxDoctor Payments Data

Jorge Pardo, MD

Neurology · Miami, FLNPI 1174658348

Payments from drug & device makers

$33,390in general payments, 2019–2025

Across 1,494 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • UCB, Inc.$2K
  • AstraZeneca$2K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • plus $19K from 54 others

What the payments were for

  • Speaking & faculty fees$1600%
  • Food & beverage$33,12699%
  • Education$1040%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)286$6,184
UCB, Inc.64$2,174
AstraZeneca(2 entities)68$1,729
Lilly USA, LLC64$1,459
Amgen(2 entities)55$1,423
Teva Pharmaceuticals USA, Inc.59$1,419
Neurocrine Biosciences, Inc.70$1,228
Biogen49$1,190
Pfizer61$1,142
Novartis48$1,044
Lundbeck LLC36$844
Acadia Pharmaceuticals Inc42$821
Argenx US, Inc.35$814
Eisai Inc.28$770
Scilex Pharmaceuticals Inc.34$702
Neurelis, Inc.33$649
SK Life Science, Inc.21$533
MDD US Operations, LLC14$450
Amneal Pharmaceuticals LLC27$442
Merz Pharmaceuticals, LLC19$416
Otsuka America Pharmaceutical, Inc.21$415
Adamas Pharmaceuticals, Inc.29$414
Impel Pharmaceuticals Inc.26$383
Johnson & Johnson7$373
Avanir Pharmaceuticals, Inc.14$368
Sunovion Pharmaceuticals Inc.19$357
Sanofi20$344
CSL Behring14$339
Acorda Therapeutics, Inc18$330
Tanabe Pharma America, Inc.11$275
Biohaven Pharmaceutical Holding Company Ltd.14$269
Supernus Pharmaceuticals, Inc.15$241
Alnylam Pharmaceuticals Inc.10$240
Kyowa Kirin, Inc.11$237
Zyla Life Sciences, Inc.14$198
Biohaven Pharmaceuticals, Inc.9$191
Almatica Pharma LLC10$181
Takeda Pharmaceuticals U.S.A., Inc.6$179
EMD Serono, Inc.8$166
GE HealthCare9$164
Upsher-smith Laboratories LLC8$162
Corium, LLC9$158
Idorsia Pharmaceuticals US Inc8$149
Akcea Therapeutics, Inc.3$148
Microvention, Inc.1$133
Azurity Pharmaceuticals, Inc.6$131
Averitas Pharma Inc.3$127
Boston Scientific4$124
Avion Pharmaceuticals7$111
Axsome Therapeutics, Inc.4$98
Harmony Biosciences LLC2$93
Alfasigma USA, Inc.4$81
GRT US Holding, Inc.3$75
Mallinckrodt Hospital Products Inc.3$68
Livanova USA, Inc.3$59
Aprecia Pharmaceuticals, LLC3$50
Inspire Medical Systems, Inc.1$49
Assertio Therapeutics, Inc.3$48
Insightec,inc2$44
Shire North American Group Inc2$38

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,390 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$695,787
Medicare patients
273
Services billed
48,212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5024$75,489
UbrelvyUbrogepant22$23,383
BotoxOnabotulinumtoxina12$17,603
Emgality PenGalcanezumab-Gnlm19$13,539
QuviviqDaridorexant Hcl11$5,472
Rasagiline Mesylate13$3,886
Memantine Hcl128$3,724
Carbidopa-LevodopaCarbidopa/Levodopa118$3,107
Memantine Hcl ErMemantine Hcl26$2,763
Gabapentin183$2,465
Duloxetine Hcl101$2,465
Pyridostigmine Bromide17$1,589
AmantadineAmantadine Hcl16$916
Primidone30$905
Pregabalin33$838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Botox$6,184$40,98634 claims
Idorsia Pharmaceuticals US IncQuviviq$149$5,47211 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$442$1,58917 claims
Upsher-smith Laboratories LLCTopiramate$162$77220 claims
Almatica Pharma LLCSertraline Hcl$181$34229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,434 neurology providers in Florida.

Other neurology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →